Expansion of New Dispensing Pharmacy Openings, Home-Based Care, Training, and Acquisitions
First written in FY2016. 17 of 34 entries say "Advanced", first in FY2017-Q2. Latest entry: 2026-08-07.
The whole theme swung hardest in 2025: 1 of 10 companies on the "Worse" side.
9 other companies' latest entry also says "Advanced".
- FY2026AdvancedAnnual report
「The pharmacy business performed steadily as a result of operating-efficiency improvements through small-scale M&A and restructuring and integration.」
In addition to small-scale M&A, operating-efficiency improvements through restructuring and integration contributed to results. Segment profit was ¥4,004 million, up 16.9% year on year. - FY2026-H1AdvancedAnnual report
「In the dispensing pharmacy business, performance remained solid, supported by operating-efficiency improvements through restructuring and integration, among other factors.」
Operating-efficiency improvements through restructuring and integration contributed to results. Revenue was ¥16,929 million and segment profit was ¥1,976 million, with segment profit up 27.8% from the previous interim period. - FY2025-H1RestatedAnnual report
「In the dispensing pharmacy business, the company pursued new store openings and operating-efficiency improvements, but profit declined because of the impact of drug price revisions and higher procurement costs, among other factors.」
New store openings and operating-efficiency improvements continued, but profit declined because of the impact of drug price revisions and higher procurement costs. - FY2024-Q3RestatedAnnual report
「In the dispensing pharmacy business, performance remained solid, supported by new store openings and small-scale M&A, among other factors.」
The existing measures to expand and operate the dispensing pharmacy business through new store openings and small-scale M&A have been reaffirmed. - FY2024-Q2RestatedAnnual report
「In the dispensing pharmacy business, performance remained solid, supported by new store openings and small-scale M&A, among other factors.」
The existing measures to expand and operate the dispensing pharmacy business through new store openings and small-scale M&A have been reaffirmed. - FY2024-Q1RestatedAnnual report
「In the dispensing pharmacy business, performance remained solid, supported by new store openings and operating-efficiency improvements, among other factors.」
The existing policy of operating and expanding the dispensing pharmacy business through new store openings and operating-efficiency improvements has been reaffirmed. - FY2023-Q2RestatedAnnual report
「In the dispensing pharmacy business, small-scale M&A and operating-efficiency improvements were implemented, but performance remained weak because of the impact of drug price revisions and the recording of upfront costs associated with new store openings.」
Small-scale M&A, operating-efficiency improvements and new store openings continue, but the company described performance as weak because of drug price revisions and upfront costs for new store openings. - FY2023-Q1RestatedAnnual report
「In the dispensing pharmacy business, performance remained solid, supported by new store openings and operating-efficiency improvements, among other factors.」
The company has reaffirmed its policy of expanding the dispensing pharmacy business through new store openings and operating-efficiency improvements. - FY2022RestatedAnnual report
「In the dispensing pharmacy business, we will improve the operating efficiency of existing stores through home-visit dispensing and other measures, secure transaction volume through new store development and improve procurement efficiency.」
The policy of combining home-visit dispensing, efficiency improvements at existing stores, new store development and procurement efficiency has been reaffirmed. The company also noted solid performance resulting from new store openings and small-scale M&A. - FY2022-Q2AdvancedAnnual report
「In the dispensing pharmacy business, performance remained solid as restrictions on visits to medical institutions eased compared with the same period of the previous year, supported by new store openings and M&A of small-format stores, among other factors.」
In addition to new store openings, the company carried out M&A of small-format stores, concretely expanding the store network and operating platform of the dispensing pharmacy business. - FY2022-Q1RestatedAnnual report
「In the dispensing pharmacy business, performance remained solid as restrictions on visits to medical institutions eased compared with the previous year’s corresponding period, supported by improved operating efficiency, among other factors.」
The company explained that the dispensing pharmacy business remained solid as restrictions on visits to medical institutions eased and operating efficiency improved. - FY2021AdvancedAnnual report
「In the dispensing pharmacy business, we will improve the operating efficiency of existing stores through home-visit dispensing and other measures, secure transaction volume through new store development and improve procurement efficiency.」
In addition to existing new store openings and operating-efficiency measures, home-visit dispensing, new store development and procurement efficiency are presented as concrete initiatives going forward. - FY2021-Q3RestatedAnnual report
「In the dispensing pharmacy business, despite the impact of drug price revisions, performance remained solid as restrictions on visits to medical institutions eased from the beginning of the fiscal year, supported by improved operating efficiency, among other factors.」
Despite the impact of drug price revisions, the business remained solid as restrictions on visits to medical institutions eased and operating efficiency improved. Revenue was ¥20,167 million and segment profit was ¥2,047 million, but no milestones for new store openings, acquisitions or similar initiatives were indicated. - FY2021-Q2AdvancedAnnual report
「In the dispensing pharmacy business, despite the impact of drug price revisions, performance remained solid as restrictions on visits to medical institutions eased from the beginning of the second quarter, supported by stronger sales of infectious disease prevention products and improved operating efficiency, among other factors. As a result, revenue was ¥13,205 million, down 1.3% from the previous year’s corresponding cumulative consolidated period, while segment profit (operating profit) was ¥1,299 million, up 1.5%.」
In addition to the existing operating-efficiency measures, stronger sales of infectious disease prevention products were identified as a concrete initiative, and segment profit increased 1.5% year on year. - FY2020AdvancedAnnual report
「In the dispensing pharmacy business, performance remained solid, supported by small-scale M&A and ongoing operating-efficiency improvement measures, among other factors. As a result, revenue was ¥27,050 million, up 5.7% from the previous consolidated fiscal year, and segment profit (operating profit) was ¥2,661 million, up 21.4%.」
Small-scale M&A and ongoing operating-efficiency measures were implemented, with revenue up 5.7% year on year and segment profit up 21.4%. - FY2020-Q3RestatedAnnual report
「In the dispensing pharmacy business, performance remained solid, supported by small-scale M&A and ongoing operating-efficiency improvement measures, among other factors. As a result, revenue was ¥20,285 million, up 6.3% from the previous year’s corresponding cumulative consolidated period, and segment profit (operating profit) was ¥1,946 million, up 25.5%.」
The company explained that ongoing small-scale M&A and operating-efficiency measures contributed to increases in revenue and segment profit. - FY2020-Q2AdvancedAnnual report
「In the dispensing pharmacy business, performance remained solid as a result of new store openings and operating-efficiency improvements such as joint procurement. As a result, revenue was ¥13,380 million, up 8.3% from the previous year’s corresponding cumulative consolidated period, and segment profit (operating profit) was ¥1,280 million, up 34.4%.」
In addition to the existing measures of new store openings and operating-efficiency improvements, joint procurement was identified as a concrete efficiency measure, and profit increased 34.4% year on year. - FY2020-Q1RestatedAnnual report
「In the dispensing pharmacy business, the impact of revised dispensing fees was less severe than in the previous year, but the operating environment remained challenging, partly because a rise in the consumption tax rate was anticipated. As a result, revenue was ¥6,621 million, up 6.1% from the previous year’s corresponding cumulative consolidated period, and segment profit (operating profit) was ¥624 million, up 25.4%.」
The impact of revised dispensing fees was less severe than in the previous year, but the operating environment remained challenging because of the anticipated consumption tax increase, among other factors. Meanwhile, revenue and segment profit exceeded the previous year’s corresponding period. - FY2019-Q3AdvancedAnnual report
「In the dispensing pharmacy business, the number of stores increased through new store openings and small-scale M&A, while ongoing operating improvements were implemented. However, performance remained challenging because of the impact of revised dispensing fees.」
The number of stores increased through new store openings and small-scale M&A, and expansion measures for the dispensing pharmacy business progressed concretely. Meanwhile, the company described performance as challenging because of the impact of revised dispensing fees. - FY2019-Q2RestatedAnnual report
「In the dispensing pharmacy business, plans for new store openings and ongoing operating-efficiency improvement measures were implemented, but performance remained challenging because of the impact of revised dispensing fees. As a result, revenue was ¥12,350 million, down 1.8% from the previous year’s corresponding cumulative consolidated period, and segment profit (operating profit) was ¥953 million, down 29.2%.」
Plans for new store openings and ongoing operating-efficiency improvement measures were implemented, but revenue and segment profit fell below the previous year’s corresponding period because of the impact of revised dispensing fees, and challenging conditions continue. - FY2019-Q1RestatedAnnual report
「In the dispensing pharmacy business, ongoing operating-efficiency improvement measures were implemented, but performance remained weak because of the impact of revised dispensing fees. As a result, revenue was ¥6,242 million, down 0.6% from the previous year’s corresponding cumulative consolidated period, and segment profit (operating profit) was ¥498 million, down 19.0%.」
Ongoing operating-efficiency improvement measures were implemented, but revenue and segment profit fell below the previous year’s corresponding period because of the impact of revised dispensing fees. - FY2018AdvancedAnnual report
「In the dispensing pharmacy business, operating efficiency improved as a result of ongoing business improvements, while M&A also proved effective, and performance remained solid. As a result, revenue was ¥25,789 million, up 6.9% from the previous consolidated fiscal year, and segment profit (operating profit) was ¥2,826 million, up 23.7%.」
Revenue and segment profit increased as a result of improved operating efficiency through ongoing business improvements and the effects of M&A. - FY2018-Q3AdvancedAnnual report
「In the dispensing pharmacy business, M&A and new store openings proved effective, and performance remained solid. As a result, revenue was ¥19,188 million, up 6.2% from the previous year’s corresponding cumulative consolidated period, and segment profit (operating profit) was ¥2,122 million, up 23.6%.」
The effects of M&A and new store openings continued, with revenue up 6.2% year on year and segment profit up 23.6%. - FY2018-Q2AdvancedAnnual report
「In the dispensing pharmacy business, M&A and new store openings proved effective, and performance remained solid. As a result, revenue was ¥12,579 million, up 6.1% from the previous year’s corresponding cumulative consolidated period, and segment profit (operating profit) was ¥1,346 million, up 28.9%.」
The effects of M&A and new store openings continued, with revenue up 6.1% year on year and segment profit up 28.9%. - FY2018-Q1AdvancedAnnual report
「In the dispensing pharmacy business, M&A and new store openings proved effective, and performance remained solid. As a result, revenue was ¥6,283 million, up 7.6% from the previous year’s corresponding cumulative consolidated period, and segment profit (operating profit) was ¥615 million, up 45.1%.」
The effects of M&A and new store openings continued, with revenue in the dispensing pharmacy business up 7.6% year on year and segment profit up 45.1%. - FY2017-Q3RestatedAnnual report
「In the dispensing pharmacy business, despite the impact of drug price revisions, performance remained solid, supported by efficiency improvements at existing stores and progress in certification as family pharmacies, among other factors.」
Despite the impact of drug price revisions, progress in improving existing-store efficiency and certification as family pharmacies continues to be cited as an effective initiative. - FY2017-Q2AdvancedAnnual report
「Meanwhile, efficiency improvements at existing stores and progress in certification as family pharmacies also proved effective, substantially reducing the rate of profit decline compared with the first-quarter cumulative consolidated period.」
In addition to improving the efficiency of existing stores, progress in certification as family pharmacies has reduced the rate of profit decline following the revision of dispensing fees. - FY2017-Q1Cited as achievedAnnual report
「In the dispensing pharmacy business, M&A and new store openings carried out in the previous fiscal year contributed to results, but profit declined because of the impact of revisions to dispensing fees.」
The contribution of M&A and new store openings in prior fiscal years is cited, while lower profit resulting from the revision of dispensing fees is also noted. - FY2016First statedAnnual report
「As a Group, we will improve the efficiency of store operations, strengthen planning projects such as medical malls, promote the use of generic drugs and develop new stores.」
An expansion strategy combining store efficiency improvements, medical malls, generic drugs and new store development. The company is also strengthening home care services and employee training.